Market Overview:
The recombinant human growth hormone (rhGH) market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market is segmented by type, application, and region. By type, the market is divided into powder and solvent. The powder segment is expected to grow at a higher CAGR than the solvent segment during the forecast period. By application, the market is classified into growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, Prader Willi syndrome (PWS), small for gestational age (SGA), SHOX deficiency, and others. Some of the major factors driving this market are increasing prevalence of Growth Hormone Deficiency (GHD) & other disorders; rising demand for rhGH therapy; technological advancements in manufacturing process; growing awareness about benefits associated with rhGH therapy among patients & physicians; increasing number of approvals for recombinant human growth hormones by regulatory authorities across regions;.
Product Definition:
A recombinant protein is a protein produced by genetic engineering, as opposed to the traditional method of extracting proteins from natural sources. Recombinant human growth hormone (rhGH) is a pharmaceutical agent used in the treatment of various medical conditions, most notably dwarfism and short stature. It is also used to treat children born small for gestational age (SGA).
Powder:
Powder is a form of GH (growth hormone) that has been extracted from the pituitary glands of cattle. It is sold as a dry powder and reconstituted with sterile water for injection into the body. Growth Hormone (GH) plays an important role in growth regulation in humans, wherein it promotes linear growth & development, enhances adult height, preventspremature aging & reduces fat mass.
Solvent:
Solvent is any substance used to dissolve another substance so that it can be absorbed, transported, or processed. The most common solvents are water and alcohols. In the case of recombinant human growth hormone (r-hGH), the solvent used for extraction is usually ethanol because it has a better rate of absorption compared to water.
Application Insights:
The others segment held the largest share of application market in 2017. This is due to the presence of other applications such as growth hormone deficiency (GHD), Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and small for gestational age. The use of recombinant human GH has increased significantly owing to its benefits over conventional therapy in treating GHD and improving lean body mass. In addition, it also improves bone density and reduces fat mass leading to improved quality of life.
However, growth hormone deficiency is expected to have the highest CAGR during the forecast period due largely on increasing awareness among patients & healthcare professionals coupled with rising incidences across all regions including North America & Europe where prevalence rate varies from 0.5% - 1%.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of companies coupled with high R&D investment and technological advancements are some factors responsible for its dominance. Moreover, increasing prevalence of growth hormone deficiency disorders is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising awareness about diagnosis and treatment options, availability of effective therapies, improving healthcare infrastructure along with growing economy in this region. In addition, an increase in investments by various governments for development of biotechnology industry can also be attributed towards rapid expansion witnessed by this sector thus far in Asia Pacific region of interest (ROI).
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace and this is expected to drive the demand for recombinant human growth hormone (rhGH) products in the coming years.
- Growing awareness about benefits of rhGH therapy: There is growing awareness among people about the benefits of rhGH therapy, which is likely to boost the market growth in the near future.
- Rising prevalence of Growth Hormone Deficiency (GHD): The prevalence of GHD is rising globally, which is anticipated to create lucrative opportunities for players operating in the recombinant human growth hormone market over the forecast period.
- Technological advancements: With technological advancements taking place across various sectors, manufacturers are introducing innovative recombinant human growth hormone products in order to cater to unmet needs of patients suffering from GHD and other medical conditions associated with low levels of GH production. This will help fuel market expansion during the forecast period. 5) Growing demand for off-label indications: Off-label indications are increasingly being prescribed by physicians owing to their better efficacy as compared to approved indications, thereby propelling demand for recombinant human growth hormone products globally
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Growth Hormone Market Research Report
By Type
Powder, Solvent
By Application
Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others
By Companies
Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F.Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology, BioPartners
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Growth Hormone Market Report Segments:
The global Recombinant Human Growth Hormone market is segmented on the basis of:
Types
Powder, Solvent
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Growth Hormone Deficiency (GHD), Turner Syndrome, Chronic Renal Insufficiency, Prader Willi Syndrome, Small for Gestational Age, SHOX Deficiency, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Pfizer
- Eli Lilly
- Merck Serono
- F.Hoffmann-La Roche
- Ferring Pharmaceuticals
- GeneScience Pharmaceuticals
- Ipsen
- LG Life Sciences
- Sandoz International
- Anhui Anke Biotechnology
- BioPartners
Highlights of The Recombinant Human Growth Hormone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Powder
- Solvent
- By Application:
- Growth Hormone Deficiency (GHD)
- Turner Syndrome
- Chronic Renal Insufficiency
- Prader Willi Syndrome
- Small for Gestational Age
- SHOX Deficiency
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Growth Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human growth hormone (rhGH) is a synthetic form of the hormone that is produced in the laboratory. It is available as a prescription drug to treat children and adults with growth disorders, such as short stature or dwarfism.
Some of the major players in the recombinant human growth hormone market are Novo Nordisk, Pfizer, Eli Lilly, Merck Serono, F.Hoffmann-La Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Sandoz International, Anhui Anke Biotechnology, BioPartners.
The recombinant human growth hormone market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Recombinant Human Growth Hormone Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Recombinant Human Growth Hormone Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Recombinant Human Growth Hormone Market - Supply Chain
4.5. Global Recombinant Human Growth Hormone Market Forecast
4.5.1. Recombinant Human Growth Hormone Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Recombinant Human Growth Hormone Market Size (000 Units) and Y-o-Y Growth
4.5.3. Recombinant Human Growth Hormone Market Absolute $ Opportunity
5. Global Recombinant Human Growth Hormone Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
5.3.1. Powder
5.3.2. Solvent
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Recombinant Human Growth Hormone Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
6.3.1. Growth Hormone Deficiency (GHD)
6.3.2. Turner Syndrome
6.3.3. Chronic Renal Insufficiency
6.3.4. Prader Willi Syndrome
6.3.5. Small for Gestational Age
6.3.6. SHOX Deficiency
6.3.7. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Recombinant Human Growth Hormone Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Recombinant Human Growth Hormone Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Recombinant Human Growth Hormone Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Recombinant Human Growth Hormone Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Recombinant Human Growth Hormone Demand Share Forecast, 2019-2026
9. North America Recombinant Human Growth Hormone Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Recombinant Human Growth Hormone Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
9.4.1. Growth Hormone Deficiency (GHD)
9.4.2. Turner Syndrome
9.4.3. Chronic Renal Insufficiency
9.4.4. Prader Willi Syndrome
9.4.5. Small for Gestational Age
9.4.6. SHOX Deficiency
9.4.7. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
9.7.1. Powder
9.7.2. Solvent
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Recombinant Human Growth Hormone Demand Share Forecast, 2019-2026
10. Latin America Recombinant Human Growth Hormone Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Recombinant Human Growth Hormone Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
10.4.1. Growth Hormone Deficiency (GHD)
10.4.2. Turner Syndrome
10.4.3. Chronic Renal Insufficiency
10.4.4. Prader Willi Syndrome
10.4.5. Small for Gestational Age
10.4.6. SHOX Deficiency
10.4.7. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
10.7.1. Powder
10.7.2. Solvent
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Recombinant Human Growth Hormone Demand Share Forecast, 2019-2026
11. Europe Recombinant Human Growth Hormone Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Recombinant Human Growth Hormone Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
11.4.1. Growth Hormone Deficiency (GHD)
11.4.2. Turner Syndrome
11.4.3. Chronic Renal Insufficiency
11.4.4. Prader Willi Syndrome
11.4.5. Small for Gestational Age
11.4.6. SHOX Deficiency
11.4.7. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
11.7.1. Powder
11.7.2. Solvent
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Recombinant Human Growth Hormone Demand Share, 2019-2026
12. Asia Pacific Recombinant Human Growth Hormone Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Recombinant Human Growth Hormone Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
12.4.1. Growth Hormone Deficiency (GHD)
12.4.2. Turner Syndrome
12.4.3. Chronic Renal Insufficiency
12.4.4. Prader Willi Syndrome
12.4.5. Small for Gestational Age
12.4.6. SHOX Deficiency
12.4.7. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
12.7.1. Powder
12.7.2. Solvent
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Recombinant Human Growth Hormone Demand Share, 2019-2026
13. Middle East & Africa Recombinant Human Growth Hormone Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Recombinant Human Growth Hormone Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Recombinant Human Growth Hormone Market Size and Volume Forecast by Application
13.4.1. Growth Hormone Deficiency (GHD)
13.4.2. Turner Syndrome
13.4.3. Chronic Renal Insufficiency
13.4.4. Prader Willi Syndrome
13.4.5. Small for Gestational Age
13.4.6. SHOX Deficiency
13.4.7. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Recombinant Human Growth Hormone Market Size and Volume Forecast by Type
13.7.1. Powder
13.7.2. Solvent
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Recombinant Human Growth Hormone Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Recombinant Human Growth Hormone Market: Market Share Analysis
14.2. Recombinant Human Growth Hormone Distributors and Customers
14.3. Recombinant Human Growth Hormone Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck Serono
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F.Hoffmann-La Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ferring Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GeneScience Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ipsen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. LG Life Sciences
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sandoz International
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Anhui Anke Biotechnology
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BioPartners
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook